IMGN853 + Pembrolizumab for Endometrial Cancer

Recruiting in Palo Alto (17 mi)

+2 other locations

Overseen byRebecca Porter, MD, PhD

Age: 18+

Sex: Female

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: Dana-Farber Cancer Institute

No Placebo Group

Prior Safety Data

Breakthrough Therapy

Trial Summary

What is the purpose of this trial?This research study is studying a drug combination as a possible treatment for endometrial cancer. The drugs involved in this study are: * mirvetuximab soravtansine (IMGN853) * pembrolizumab

Eligibility Criteria

This trial is for adults with advanced or recurrent serous endometrial cancer that's microsatellite stable and FRα positive. Participants must have had 1-3 prior chemotherapy treatments but not certain other drugs, and should be in good health with no serious infections or autoimmune diseases. Women must use birth control and can't be pregnant.

Inclusion Criteria

My cancer is a type of advanced or recurrent serous endometrial cancer.

I have had 1 to 3 chemotherapy treatments for endometrial cancer.

Ability to understand and the willingness to sign a written informed consent document

+11 more

Exclusion Criteria

Pregnant or nursing women

My doctor considers any other cancer I've had as cured.

I haven't taken immunosuppressive drugs in the last week, with some exceptions.

+12 more

Participant Groups

The study tests a combination of two drugs, mirvetuximab soravtansine (IMGN853) and pembrolizumab, as a treatment for endometrial cancer. It aims to see how well these drugs work together in patients who meet specific criteria.

1Treatment groups

Experimental Treatment

Group I: IMGN853 + PembrolizumabExperimental Treatment2 Interventions

* Pembrolizumab is administered intravenously once every 3 weeks * IMGN853 is administered intravenously once every 3 weeks